Zoetis [ZTS] vs Intra-Cellular [ITCI] Detailed Stock Comparison

Zoetis Inc.

NYSE
Loading...

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Zoetis Inc. wins in 13 metrics, Intra-Cellular Therapies Inc. wins in 5 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Zoetis Inc. Intra-Cellular Therapies Inc. Better
P/E Ratio (TTM) 19.58 -183.15 Zoetis Inc.
Price-to-Book Ratio 15.04 12.20 Intra-Cellular Therapies Inc.
Debt-to-Equity Ratio 279.59 1.48 Intra-Cellular Therapies Inc.
PEG Ratio 2.81 507.19 Zoetis Inc.
EV/EBITDA 13.96 -112.19 Zoetis Inc.
Profit Margin (TTM) 28.24% -10.97% Zoetis Inc.
Operating Margin (TTM) 34.69% -14.66% Zoetis Inc.
EBITDA Margin (TTM) 34.69% N/A N/A
Return on Equity 65.99% -8.58% Zoetis Inc.
Return on Assets (TTM) 15.26% -6.96% Zoetis Inc.
Free Cash Flow (TTM) $2.28B $-73.50M Zoetis Inc.
Dividend Yield 1.21% N/A N/A
1-Year Return -51.58% 92.68% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) 5.26 20.63 Zoetis Inc.
Enterprise Value $56.75B $13.04B Zoetis Inc.
EV/Revenue Ratio 6.00 19.15 Zoetis Inc.
Gross Profit Margin (TTM) 70.17% 89.76% Intra-Cellular Therapies Inc.
Revenue per Share (TTM) $21 $7 Zoetis Inc.
Earnings per Share (Diluted) $6.02 $-0.73 Zoetis Inc.
Beta (Stock Volatility) 0.97 0.46 Intra-Cellular Therapies Inc.
Short % of Float 4.06% N/A N/A

Zoetis Inc. vs Intra-Cellular Therapies Inc. Stock Performance Analysis

Loading Price Chart...

ZTS
ITCI

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%

Performance & Financial Health Analysis: Zoetis Inc. vs Intra-Cellular Therapies Inc.

MetricZTSITCI
Market Information
Market Cap i$49.75B$14.05B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,727,7102,749,368
90 Day Avg. Volume i3,835,9402,309,509
Last Close$167.10$131.87
52 Week Range$139.70 - $200.33$64.09 - $131.98
% from 52W High-16.59%-0.08%
All-Time High$249.27 (Dec 27, 2021)$131.98 (Mar 31, 2025)
% from All-Time High-32.96%-0.08%
Growth Metrics
Quarterly Revenue Growth0.03%0.51%
Quarterly Earnings Growth0.04%0.51%
Financial Health
Profit Margin (TTM) i0.28%-0.11%
Operating Margin (TTM) i0.35%-0.15%
Return on Equity (TTM) i0.66%-0.09%
Debt to Equity (MRQ) i279.591.48
Cash & Liquidity
Book Value per Share (MRQ)$7.84$10.81
Cash per Share (MRQ)$5.48$9.42
Operating Cash Flow (TTM) i$2.90B$-73,177,000
Levered Free Cash Flow (TTM) i$1.79B$-63,549,624
Dividends
Last 12-Month Dividend Yield i1.21%N/A
Last 12-Month Dividend i$2.03N/A

Valuation & Enterprise Metrics Analysis: Zoetis Inc. vs Intra-Cellular Therapies Inc.

MetricZTS (Apr 13, 2026)ITCI (May 17, 2025)
Price Ratios
P/E Ratio (TTM) i19.58-183.15
Forward P/E i15.61507.19
PEG Ratio i2.81507.19
Price to Sales (TTM) i5.2620.63
Price to Book (MRQ) i15.0412.20
Market Capitalization
Market Capitalization i$49.75B$14.05B
Enterprise Value i$56.75B$13.04B
Enterprise Value Metrics
Enterprise to Revenue i6.0019.15
Enterprise to EBITDA i13.96-112.19
Risk & Other Metrics
Beta i0.970.46
Book Value per Share (MRQ) i$7.84$10.81

Financial Statements Comparison: Zoetis Inc. vs Intra-Cellular Therapies Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricZTS (2025)ITCI (2024)
Revenue/Sales i9.47B680.50M
Cost of Goods Sold i2.67B56.96M
COGS % of Revenue i28.2%8.4%
Gross Profit i6.80B623.54M
Gross Margin i71.8%91.6%
Research & Development i698.00M236.12M
Operating Income (EBIT) i3.60B-116.72M
Operating Margin i38.0%-17.2%
EBITDA i4.17B-116.21M
EBITDA Margin i44.1%-17.1%
Pre-Tax Income i3.36B-74.20M
Pre-Tax Income % of Revenue i35.5%-10.9%
Income Tax i687.00M473,000
Income Tax % of Revenue i7.3%0.1%
Net Income (Profit) i2.67B-74.68M
Profit Margin i28.2%-11.0%

Balance Sheet & Liquidity Metrics

MetricZTS (2025)ITCI (2024)
Cash & Equivalents i2.31B306.95M
Total Current Assets i6.77B1.31B
Total Current Assets % of Revenue i71.5%192.1%
Total Current Liabilities i2.24B205.70M
Total Current Liabilities % of Revenue i23.6%30.2%
Long-Term Debt i9.24B12.75M
Long-Term Debt % of Revenue i97.6%1.9%
Total Shareholders Equity i3.33B1.15B
Retained Earnings i13.74B-1.69B
Retained Earnings % of Revenue i145.2%-248.6%
Property, Plant & Equipment i288.00M14.90M

Cash Flow Statement Comparison

MetricZTS (2025)ITCI (2024)
Operating Cash Flow i2.78B-63.27M
Operating Cash Flow % of Revenue i29.3%-9.3%
Capital Expenditures iN/A-322,000
Free Cash Flow i2.28B-73.50M
FCF Margin i24.1%-10.8%
Debt Repayment i-1.35BN/A
Common Stock Repurchase i-3.24BN/A

Short Interest & Institutional Ownership Analysis

MetricZTSITCI
Shares Short i15.12MN/A
Short Ratio i3.60N/A
Short % of Float i4.06%N/A
Shares Outstanding i424.93M106.24M
Float Shares i421.29M104.82M
% Held by Insiders i0.15%2.48%
% Held by Institutions i101.50%96.45%
% Held by Public i-1.65%1.07%

Dividend Analysis & Yield Comparison: Zoetis Inc. vs Intra-Cellular Therapies Inc.

MetricZTSITCI
Last 12-Month Dividend i$2.03N/A
Last 12-Month Dividend Yield i1.21%N/A
3-Year Avg Annual Dividend i$1.80N/A
3-Year Avg Dividend Yield i0.29%N/A
3-Year Total Dividends i$5.39N/A
Ex-Dividend DateJan 20, 2026N/A